Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma
Perla Pucci(University of Cambridge), Suzanne D. Turner(MRC Laboratory of Molecular Biology)
Cited by 14
Related Papers
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
|Cancers|2018|86
Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|American Journal Of Pathology|2019|54
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
|Nature Communications|2019|42